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Insulin receptor substrate (IRS) proteins are major
substrates of the insulin receptor (IR). IRS-1 associates
with an insoluble multiprotein complex, possibly the
cytoskeleton, in adipocytes. This localization may facil-
itate interaction with the IR at the cell surface. In the
present study, we examined the hypothesis that the re-
lease of IRS proteins from this location may be a mech-
anism for insulin desensitization. We show that a second
IRS protein, IRS-2, is associated with a multiprotein
complex in adipocytes with similar characteristics to
the IRS-1 complex. Insulin treatment (15–60 min) caused
the release of IRS-1 and IRS-2 from this complex (high
speed pellet; HSP) into the cytosol, whereas the level of
tyrosyl-phosphorylated IRS proteins remained con-
stant. Chronic insulin treatment resulted in a dramatic
reduction in IRS-1 and IRS-2 in the HSP, eventually (>2
h) leading to IRS protein degradation and decreased
levels of tyrosyl-phosphorylated IRS proteins. Okadaic
acid, which rapidly induces insulin resistance in adipo-
cytes independently of IR function, caused an almost
quantitative release of IRS-1 into the cytosol commen-
surate with a significant reduction in tyrosyl-phospho-
rylated IRS proteins. Platelet-derived growth factor, a
factor known to compromise insulin signaling, caused a
more moderate release of IRS proteins from the HSP.
Collectively, these results suggest that the assembly of
IRS-1/IRS-2 into a multiprotein complex facilitates cou-
pling to the IR and that the regulated release from this
location may represent a novel mechanism of insulin
resistance.
The insulin receptor (IR)1 is a member of the tyrosine kinase
growth factor receptor family (1). One property that distin-
guishes the IR from other growth factor receptors is its ability
to induce the tyrosine phosphorylation of a family of intracel-
lular signaling molecules referred to as insulin receptor sub-
strate (IRS) proteins (2–5). IRS proteins contain a pleckstrin
homology domain and a phosphotyrosine binding domain, both
of which are required for the efficient tyrosine phosphorylation
of these proteins by the activated insulin receptor tyrosine
kinase (6, 7). The first member of the IRS family to be identi-
fied, IRS-1, encodes a 160-kDa protein that is highly expressed
in physiologically insulin-responsive tissues such as adipocytes
and muscle cells and has been implicated in the control of a
number of insulin-sensitive metabolic pathways including glu-
cose transport, lipid deposition, and glycogen synthesis (8). In
response to insulin, the phosphorylation of multiple tyrosine
residues within the C terminus of IRS-1 by the IR leads to the
generation of highly specific binding sites for a number of Src
homology 2 domain-containing downstream signaling mole-
cules such as phosphatidylinositide (PI) 3-kinase, Syp, Nck,
Fyn, and Grb-2 (8–10). PI 3-kinase appears to be a central
insulin-signaling molecule, because inhibition of its activity by
either pharmacological agents or dominant-negative mutants
profoundly abrogates several biological responses to this hor-
mone (11–14). In basal cells, IRS-1 is also highly phosphoryl-
ated on serine and threonine (Ser/Thr) residues, and insulin
acutely stimulates a further increase in IRS-1 Ser/Thr phos-
phorylation (4, 15). The signaling function of IRS-1 Ser/Thr
phosphorylation is unknown, although this may regulate the
docking of other types of signaling molecules such as 14-3-3
proteins (16, 17).
Defects within insulin signaling pathways comprise a major
locus for the development of insulin resistance in disease states
such as non-insulin-dependent diabetes mellitus (18). Certain
forms of insulin resistance, such as that induced by tumor
necrosis factor-a, okadaic acid, or chronic insulin treatment,
may be due to uncoupling of the IR activity toward IRS-1
(19–21). While the molecular basis for this defect is unclear, a
common observation in cells subjected to these conditions is
that IRS-1 becomes hyperphosphorylated on serine and threo-
nine residues and various intracellular Ser/Thr kinases, in-
cluding glycogen synthase kinase-3, protein kinase C-a, mito-
gen-activated protein kinase, and protein kinase B/Akt, have
been implicated in mediating this effect (22–28). The decline in
insulin sensitivity invoked by tumor necrosis factor-a has re-
cently been attributed to a dominant negative effect exerted by
hyperphosphorylated IRS-1 upon the IR intrinsic tyrosine ki-
nase (19). However, neither okadaic acid nor chronic insulin
treatment appear to disrupt IR tyrosine kinase activity in
response to acute insulin activation (20, 21, 24). These latter
observations suggest that other mechanisms may operate to
induce insulin resistance.
We have recently provided evidence to suggest that IRS-1 is
enriched in a cytoskeletal fraction in adipocytes that is insolu-
ble in a range of nonionic detergents (29). This accounts for
early reports suggesting that IRS-1 is bound to membranes,
because the cytoskeletal fraction co-fractionates with microso-
mal membranes during ultracentrifugation (30, 31). The an-
choring of IRS-1 to the cytoskeleton may be of particular im-
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portance to the efficacy of insulin signaling by providing a
platform for localizing IRS-1 within proximity to the insulin
receptor. This arrangement may also provide a robust link
between IRS-1 and downstream signaling proteins such as PI
3-kinase, which also appears to associate with this insoluble
fraction (29). One functional consequence of this spatial local-
ization is that it may create a unique site for the generation of
specific signals required for insulin action. Consistent with the
latter notion, platelet-derived growth factor (PDGF) also acti-
vates PI 3-kinase in adipocytes but has no significant effect on
PI 3-kinase-dependent functions in these cells, including glu-
cose transport and glycogen synthesis (32).
It has previously been reported that IRS-1 exists in at least
two distinct pools in adipocytes: the cytoskeletal component
and the cytosol (31, 33). Furthermore, short term insulin treat-
ment triggers the release of IRS-1 from the cytoskeletal frac-
tion into the cytosol (31). It has been argued that the cytoskel-
etal component represents the functional pool of IRS-1, because
most of the tyrosyl-phosphorylated IRS-1 is found in this pool,
and there is a net increase in PI 3-kinase in this fraction in
response to insulin (34). Hence, it may be postulated that the
deactivation of IRS-1 corresponds to its translocation from this
fraction into the cytosol. This model raises the possibility that
the cytosolic pool of IRS-1 is nonfunctional presumably due to
its inaccessibility to the IR. Therefore, inappropriate accumu-
lation of IRS-1 in the cytosol may disengage this protein from
the receptor, resulting in a state of insulin resistance. In the
present study, we have tested the notion that the intracellular
location of IRS-1 can be modified under conditions that nor-
mally cause insulin resistance and/or alter insulin signaling
potential. In addition, we have extended this hypothesis to
include the IRS-1 homologue, IRS-2, which is also expressed in
3T3-L1 adipocytes. Our results show that a significant propor-
tion of IRS-1 and IRS-2 are found in a detergent-resistant
insoluble fraction that has properties analogous to the cytoskel-
eton. Moreover, IRS proteins translocate from this location into
the cytosol following exposure of adipocytes to chronic insulin
treatment or okadaic acid or PDGF. These data suggest that
the intracellular location of IRS proteins is regulated in a way
that may influence insulin action.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—All tissue culture media was purchased
from Life Technologies, Inc., except fetal calf serum, which was ob-
tained from Trace Biosciences (Clayton, Australia). Insulin was ob-
tained from Calbiochem, and PDGF.B was from Life Technologies, Inc.
Bovine serum albumin was purchased from ICN (Costa Mesa, CA).
Unless specified, all other reagents were from Sigma. The GLUT4
polyclonal antibody (R820) was raised against a synthetic peptide as
described previously (35). The anti-phosphotyrosine monoclonal anti-
body (4G10) was kindly provided by Dr. B. Druker (Oregon Health
Sciences University, Portland, OR), and polyclonal antibodies raised
against Akt-2 were provided by Dr. M. Birnbaum (Howard Hughes
Medical Institute, Philadelphia, PA). All other antibodies used in this
study were purchased from the following sources: anti-IRS-1 polyclonal
antibody from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); anti-
p85 and anti-IRS-2 polyclonal antibodies from Upstate Biotechnology
Inc. (Lake Placid, NY); anti-hemagglutinin (HA) monoclonal antibody
from Babco (Richmond, CA); peroxidase-coupled secondary antibodies
from Amersham Pharmacia Biotech (Little Chalfont, United Kingdom).
Construction of HA-IRS-1—Full-length mouse IRS-1 cDNA in pBlue-
scriptSK, generously provided by Drs. S. Keller and G. Lienhard (Dart-
mouth Medical School, Hanover, NH), was used as template in a po-
lymerase chain reaction to generate a construct encoding IRS-1 tagged
at the C terminus with the HA epitope (HA-IRS-1). In this reaction, the
forward primer consisted of the pBluescript sequencing primer, T7,
whereas the reverse primer was comprised of the following sequence:
59-CTGCGGTCGACTAAGCGTAATCTGGAACATCGTATGGGTAAGC-
TTGACGATCCTCTGGCTGCTTCTGGAAGCTGATGCTGGC-39 (Pacif-
ic Oligos, Lismore, Australia). A cDNA fragment encoding the entire
sequence of HA-IRS-1 was then amplified using standard polymerase
chain reaction protocols. The amplified product was isolated, digested
with SalI, and subcloned into SalI sites of a eukaryotic expression
vector, pMEX (36). Clones carrying the insert in the desired orientation
were verified by restriction mapping.
Cell Culture and Treatments—3T3-L1 fibroblasts were cultured and
differentiated into adipocytes as described previously (37). Cells were
serum-starved in Dulbecco’s modified Eagle’s medium supplemented
with 0.1% bovine serum albumin and 2 mM glutamine for 2 h at 37 °C
and subsequently incubated with insulin (1 mM) for 0.25 h (acute) or for
0.25, 1, 2, or 4 h (chronic) or with PDGF (50 ng/ml) for 1 h at 37 °C.
Where indicated, cells were incubated with wortmannin (100 nM) for 15
min and then insulin (1 mM) and wortmannin for 1 h at 37 °C. Medium
was replaced with medium containing fresh wortmannin (100 nM) and
insulin (1 mM) 30 min prior to harvesting cells. In other experiments,
cells were incubated with okadaic acid (2.5–5.0 mM) for 30 min, during
which insulin (1 mM) was added to the incubation medium for the last 15
min. In glucose uptake assays, 3T3-L1 adipocytes were serum-starved
in Krebs-Ringer phosphate buffer (2.5 mM HEPES (pH 7.4), 120 mM
NaCl, 6 mM KCl, 1.2 mM MgSO4, 10 mM CaCl2, 0.4 mM NaH2PO4, 0.6
mM Na2HPO4), KRP, containing 0.1% bovine serum albumin and 3.0
mM sodium pyruvate, for 2 h at 37 °C. Cells were then incubated with
PDGF (50 ng/ml) for 1 h and subsequently incubated with insulin (1 mM)
for a further 15 min.
CHO cells overexpressing the insulin receptor (CHO-IR) were kindly
donated by Dr. M White (Harvard Medical School, Boston, MA) and
were maintained in culture as described previously (29). Prior to trans-
fection, cells were seeded in 60-mm dishes and grown for a further 24 h
to achieve 60–80% confluence. Transient transfections were performed
by incubating cells in medium (Dulbecco’s modified Eagle’s medium,
nonessential amino acids, 2 mM L-glutamine) containing 6 mg of HA-
IRS-1/pMEX and 30 ml of Lipofectamine reagent for 5 h at 37 °C.
Transfection medium was then replaced with CHO cell culture media,
and cells were grown to 100% confluence. Transfected cells were sub-
sequently serum-starved and exposed to chronic insulin treatment as
described above for adipocytes. In preliminary experiments, immuno-
fluorescence studies of CHO-IR cells transfected with HA-IRS-1 cDNA
showed that at least 20–30% of cells expressed full-length HA-IRS-1
protein.
Cell Fractionation—After incubation with the appropriate agents,
3T3-L1 adipocytes were washed three times with ice-cold HES buffer
(20 mM HEPES (pH 7.4), 1 mM EDTA, 250 mM sucrose) and homoge-
nized in the same buffer supplemented with phosphatase and protease
inhibitors (2 mM sodium orthovanadate, 10 mM sodium fluoride, 1 mM
tetra-sodium pyrophosphate, 1 mM ammonium molybdate, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 250 mM phenylmethylsulfonyl fluoride).
Subcellular fractions were isolated by differential centrifugation as
previously detailed (37). All procedures were performed at 4 °C. Briefly,
cell homogenates were centrifuged at 13,000 3 g for 20 min. The
resulting pellet was then resuspended in HES buffer and layered onto
a 1.12 M sucrose cushion as described by Piper et al. (37). After centrif-
ugation at 77,000 3 g for 1 h, the plasma membrane fraction was
collected from the 1.12 M sucrose interface. The supernatant from the
13,000 3 g centrifugation step was subjected to centrifugation at
30,000 3 g for 30 min to pellet the high density microsomal fraction.
The resultant supernatant was subjected to further centrifugation at
175,000 3 g for 75 min to obtain the high speed pellet (HSP). The
supernatant from this centrifugation step was designated the cytosol
fraction. The membrane pellets were solubilized with 1% SDS in PBS.
In some experiments, the HSP fraction from 3T3-L1 adipocytes was
resuspended and incubated in HES containing 1% Triton X-100 (Pierce)
for 1 h on ice. Insoluble material was collected by centrifugation at
175,000 3 g for 75 min at 4 °C, and the resultant pellet was solubilized
in 1% SDS in PBS.
CHO-IR cells overexpressing HA-IRS-1 were subjected to chronic
insulin treatment, and the HSP from these cells was obtained as de-
scribed previously (29) with some modifications. All steps were per-
formed at 4 °C. Cells were washed in ice-cold HES and then homoge-
nized in HES buffer containing phosphatase and protease inhibitors by
passage through a 22-gauge needle. The homogenate was subjected to
centrifugation at 17,500 3 g for 15 min to remove high density micro-
somes, plasma membranes, mitochondria/nuclei, and cell debris. The
supernatant was then centrifuged at 175,000 3 g for 75 min. The
resultant supernatant was designated the cytosol. The pellet (HSP),
was solubilized in 1% SDS in PBS.
Immunoblotting and Densitometry Analysis—The amount of protein
present in all samples was determined using BCA reagent (Pierce).
Samples were subjected to SDS-PAGE (38) and transferred to Immo-
bilon-P polyvinylidene difluoride membranes (Millipore Corp., Bedford,
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MA). Membranes were blocked with 3% bovine serum albumin in TBST
buffer (20 mM TriszHCl (pH 7.6), 150 mM NaCl, 0.05% Tween 20)
(anti-phosphotyrosine antibody) or with 5% skim milk powder in PBS
buffer (all other antibodies). The membranes were incubated with pri-
mary antibody, washed, and then incubated with the appropriate horse-
radish peroxidase-coupled secondary antibody for 30 min at room tem-
perature. Immunoreactive proteins were visualized by autoradiography
using enhanced chemiluminescence (Supersignal, Pierce, or ECL Plus,
Amersham Pharmacia Biotech), according to the instructions from the
manufacturer. The protein bands were quantified by densitometry (GS-
700 Imaging densitometer, Bio-Rad) using nonsaturated exposed x-ray
films. Statistical analysis of the data was performed using Microsoft
Excel software. All data are presented as the mean value.
Glucose Uptake Assays—2-Deoxy-[3H]glucose uptake was measured
as described previously (39). Briefly, 3T3-L1 adipocytes were treated in
the absence or presence of growth factor in 950 ml of KRP containing 1%
bovine serum albumin and 3.0 mM sodium pyruvate. The assay was
initiated by adding 50 ml of 1 mM 2-deoxy-[3H]glucose (20 mCi/mmol)/
KRP and, after 3 min, was terminated by washing cells rapidly three
times with ice-cold PBS. Cells were subsequently solubilized in 1%
Triton X-100, and 3H was quantitated by scintillation counting (Pack-
ard 1900CA liquid scintillation analyzer, Packard Instrument Co.).
Glucose uptake was measured in duplicate in all treatments. Nonspe-
cific uptake of 2-deoxy-[3H]glucose was determined by adding 50 mM
cytochalasin B to the appropriate controls prior to the commencement of
assays.
RESULTS
Subcellular Distribution of IRS-1 Versus IRS-2 in 3T3-L1
Adipocytes—In basal adipocytes, IRS-1 is enriched in a micro-
somal fraction, often referred to as the low density microsomes
(31, 33, 40). In addition to intracellular membranes that con-
tain the insulin-regulatable glucose transporter, GLUT4, the
low density microsomes fraction also contains cytoskeleton and
other large protein complexes. In fact, .60% of the protein in
this fraction is insoluble in nonionic detergents, so we now refer
to this fraction as the high speed pellet, or HSP (41). In contrast
to membrane proteins such as GLUT4, IRS-1 remains insoluble
following treatment of the HSP with nonionic detergents, and it
does not have a buoyant density that enables it to float up
through a 50% sucrose solution (29). Based on these data, we
proposed that IRS-1 is either attached to the cytoskeleton or
found in a large protein complex that enables it to be pelleted
during high speed centrifugation.
In certain cellular contexts, IRS-2 may functionally substi-
tute for IRS-1 in mediating insulin action (42). In 3T3-L1
adipocytes, the subcellular distribution of IRS-2 is indistin-
guishable from IRS-1 (Fig. 1A). Consistent with recent studies
(34, 43), we observed a significant amount (60–80% of the
total) of both IRS-1 and IRS-2 in the HSP fraction in basal
adipocytes. Low levels were found in the plasma membrane
and high density microsome fractions, possibly due to contam-
ination of these fractions with HSP-derived material. Signifi-
cant levels (20–40%) of both IRS-1 and IRS-2 were found in the
cytosol under basal conditions. Consistent with previous stud-
ies (31, 34), both IRS-1 and IRS-2 were released from the HSP
into the cytosol upon acute treatment of the cells with insulin
(Fig. 1A). The HSP pool of IRS-2 exhibited similar biochemical
properties to that of IRS-1, in that it remained insoluble fol-
lowing treatment with the nonionic detergent, Triton X-100
(Fig. 1B). In addition, flotation analysis of the HSP as described
previously (29) showed that, in contrast to membrane-associ-
ated proteins but identical to IRS-1, IRS-2 does not float up
through a 50% sucrose solution (data not shown). These data
are consistent with a model where the HSP pool of both IRS-1
and IRS-2 are not membrane-associated.
Effects of Chronic Insulin Treatment on the Subcellular Dis-
tribution of IRS Proteins—As depicted in Fig. 1A and described
in more recent studies (34), both IRS-1 and IRS-2 undergo
acute insulin-stimulated release from the HSP into the cytosol.
With extended insulin treatment (15–60 min), there was sig-
nificant loss of immunoreactive IRS-1 and IRS-2 from the HSP
(.80%), but the amount of tyrosine-phosphorylated IRS pro-
teins remained fairly constant during this time (Fig. 2, A and
B). This suggests that a relatively small component of the total
IRS protein pool is tyrosine-phosphorylated in response to in-
sulin at steady state and that this pool of IRS proteins is
maintained despite a marked loss of immunoreactive protein
from the HSP fraction following prolonged exposure to insulin.
The amount of IRS proteins in the HSP continued to decline in
response to long term exposure to insulin, and it was not until
the cells had been incubated in the presence of insulin for up to
4 h before there was a significant decrease in tyrosine-phos-
phorylated IRS proteins in the HSP fraction (Fig. 2, A and B).
This corresponded to the time of onset of insulin resistance as
determined by the amount of the insulin-regulatable glucose
transporter, GLUT4, in the plasma membrane (Fig. 2D), and
the amount of immunoreactive p85 in the HSP fraction that
also declined at the 4-h time point (Fig. 2A). A similar time
course of insulin-induced insulin resistance in 3T3-L1 adipo-
cytes has been reported by other groups (21, 24).
Commensurate with the loss of IRS-1 and IRS-2 from the
HSP in response to insulin, we observed a significant increase
in the cytosolic fraction (Fig. 2C). This increase in cytosolic IRS
proteins peaked after 1 h of insulin treatment and declined
thereafter. We did not observe a corresponding increase in the
level of either IRS-1 or IRS-2 in any other fraction (data not
shown), suggesting that this loss reflects degradation of the
IRS proteins. The rate of decline in cytosolic IRS-1 was consid-
erably more rapid than that of cytosolic IRS-2, suggesting that
the degradation of the two IRS isoforms following chronic in-
sulin exposure may be controlled by distinct mechanisms. The
release of IRS-1 and IRS-2 from the HSP in response to insulin
was accompanied by a significant decrease in the electro-
phoretic mobility of both proteins (Fig. 2A). This was quite
evident in the HSP fraction after only 15 min of incubation with
insulin. Interestingly, there appeared to be a stepwise decrease
FIG. 1. IRS-1 and IRS-2 are enriched in a detergent-insoluble
high speed pellet fraction isolated from adipocytes. Adipocytes
were incubated in the absence (2) or presence (1) of insulin (1 mM) for
15 min, homogenized, and subjected to differential centrifugation to
yield fractions enriched in plasma membranes (PM), high density mi-
crosomes (HDM), cytosol (CYT), and a high speed pellet (HSP) fraction.
A, fractions (20 mg of protein) were resolved by SDS-PAGE and immu-
noblotted with antisera specific for IRS-1 and IRS-2. B, the HSP frac-
tion isolated from basal (2) or insulin-treated (1) adipocytes was incu-
bated in HES buffer (20 mM HEPES, 1 mM EDTA, 250 mM sucrose, pH
7.4) or HES buffer containing 1% Triton X-100 (Tx-100) at 4 °C for 1 h,
and the insoluble material was pelleted by centrifugation at 175,000 3
g. The resultant pellets were analyzed by SDS-PAGE and immuno-
blotted with antibodies against IRS-1 and IRS-2.
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in the mobility of both IRS-1 and IRS-2 with time: this was
most clearly observed in the cytosol (compare 0.25- versus 1-h
insulin exposure).
To verify the above findings in a heterologous system, CHO
cells overexpressing the IR (CHO-IR) were transfected with a
hemagglutinin-tagged IRS-1 cDNA (HA-IRS-1), and replicated
the above experimental regimen. When expressed in CHO-IR
cells, the HA-IRS-1 protein was tyrosyl-phosphorylated in re-
sponse to insulin, suggesting that it forms a competent IR
substrate under these conditions (data not shown). As indi-
cated in Fig. 3A, an anti-HA antibody immunolabeled a protein
that corresponded to a molecular mass of 170 kDa in CHO cells
transfected with HA-IRS-1, whereas no specific band was de-
tected in control cells (not shown). HA-IRS-1 was distributed
between the HSP fraction and the cytosol in CHO cells, con-
sistent with the distribution of IRS-1 and IRS-2 in adipocytes.
Insulin treatment caused translocation of HA-IRS-1 from the
HSP fraction into the cytosol in CHO-IR cells, with a time
course comparable with that observed in adipocytes (Fig. 3B).
After 2 h of insulin treatment, the level of HA-IRS-1 in the HSP
was reduced to ,20% of that found under basal conditions.
Initially, there was an increase in HA-IRS-1 in the cytosol in
response to insulin that was presumably derived from the HSP.
However, as was the case in adipocytes for both IRS-1 and
IRS-2, after 1 h of prolonged insulin treatment (Fig. 2C), the
level of HA-IRS-1 in the cytosol declined, presumably indica-
tive of net loss of the protein from the cell. This was not due to
nonspecific degradation of the recombinant protein, because in
cells maintained at basal conditions for the 4-h time period,
levels of HA-IRS-1 were not significantly altered (data not
shown). These data suggest that the targeting of IRS-1 to an
insoluble intracellular location as well as its regulated release
from this site, can be reconstituted in other cell types that are
not normally considered to be bona fide insulin-sensitive cells.
Whereas chronic insulin treatment caused a stepwise decrease
in the mobility of IRS-1 in the HSP fraction isolated from
3T3-L1 adipocytes (Fig. 2A), no such change in the mobility of
HA-IRS-1 could be detected in the HSP isolated from CHO-IR
cells (Fig. 3A). This did not appear to be due to an inability to
detect a mobility shift of HA-IRS-1, because a shift was ob-
served in the mobility of HA-IRS-1 present in the cytosolic pool.
Effects of Wortmannin on the Insulin-dependent Release of
IRS Proteins from the HSP—To test the role of PI 3-kinase or
of signaling proteins downstream of this enzyme in the insulin-
dependent release of IRS-1 and IRS-2 from the HSP, we looked
at the effects of the PI 3-kinase inhibitor, wortmannin, on this
process. Wortmannin at a concentration of 100 nM had no
significant effect on the insulin-dependent release of IRS-1 or
IRS-2 from the HSP (Fig. 4A). The efficacy of wortmannin
inhibition during these treatments was confirmed by the ab-
sence of an electrophoretic shift in cytosolic Akt-2, a PI 3-kinase-
dependent serine kinase (Fig. 4B) (44). Similar data were ob-
tained using an alternate PI 3-kinase inhibitor, LY294002 (not
shown). While we did not observe a significant effect of wort-
mannin on the insulin-stimulated release of IRS proteins in six
experiments, in three of these studies we observed a modest
increase in the amount of IRS-1 and IRS-2 associated with the
HSP in cells treated with wortmannin alone (Fig. 4A). Never-
theless, while these data suggest that the association of IRS
proteins with the HSP may be regulated by a wortmannin-
sensitive factor in the basal state, this is not the mechanism for
the release of IRS proteins in response to insulin.
FIG. 2. Effects of chronic insulin treatment on the subcellular
distribution of IRS-1, IRS-2, PI 3-kinase, and GLUT4 in 3T3-L1
adipocytes. 3T3-L1 adipocytes were incubated with insulin (1 mM) for
various times (0–4 h). Cells were homogenized, and the cytosol and
high speed pellet (HSP) were prepared by subcellular fractionation. A,
aliquots of the HSP (30 mg of protein) and cytosol (20 mg of protein) were
resolved by SDS-PAGE and immunoblotted with antibodies specific for
IRS-1, IRS-2, phosphotyrosine (PY), and PI 3-kinase (p85). The phos-
photyrosine antibody labels a 180-kDa band, which corresponds to IRS
proteins. Immunoreactive IRS-1 (l ), IRS-2 (E), and phosphotyrosine-
IRS () present in the HSP (B) and cytosol fractions (C), respectively,
were quantified by densitometry and expressed as a percentage of the
maximum value. The mean values from at least three independent
experiments are shown. D, immunoreactive GLUT4 present in PM (l )
or HSP (E) fractions was quantified by densitometry and expressed as
a percentage of the maximum value. The mean values from three
independent experiments are shown.
FIG. 3. Effects of chronic insulin treatment on the subcellular
distribution of HA-IRS-1 expressed in CHO-IR cells. CHO-IR cells
were transiently transfected with an HA-tagged IRS-1 cDNA. Cells
were incubated with insulin (1 mM) for different times (0–4 h), lysed,
and subjected to differential centrifugation to obtain the high speed
pellet (HSP) fraction and cytosol. A, aliquots (30 mg) of each fraction
were resolved by SDS-PAGE and immunoblotted with antibodies spe-
cific for HA. B, immunoreactive HA-IRS-1 was quantified by densitom-
etry, and expressed as a percentage of the maximum value present in
the HSP (l ) or cytosol (E) fractions. Data shown are representative of
two separate experiments.
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Effects of Okadaic Acid on the Subcellular Distribution of
IRS Proteins—Okadaic acid, a serine/threonine phosphatase
inhibitor, induces insulin resistance in both adipocytes and
muscle cells and potently inhibits insulin-regulated glucose
transport by blocking the translocation of GLUT4 (20, 23, 45,
46). Consistent with these studies, we also observed a substan-
tial reduction in the level of insulin-stimulated glucose uptake
in 3T3-L1 adipocytes in the presence of 2.5–5.0 mM okadaic acid
(data not shown). In further agreement with previous studies
(23), okadaic acid induced a significant shift in the electro-
phoretic mobility of IRS-1 (Fig. 5). Okadaic acid also caused the
release of .90% of IRS-1 from the HSP. This was accompanied
by a large increase in IRS-1 in the cytosol fraction. A similar
distribution of IRS-1 was observed in cells treated with okadaic
acid plus insulin (Fig. 5). Consistent with the hypothesis that
the HSP pool of IRS-1 interacts with the IR, we observed no
detectable insulin-stimulated tyrosine phosphorylation of
IRS-1 in the cytosol after treatment with okadaic acid, despite
a considerable proportion of the protein in this fraction (Fig. 5).
Insulin-stimulated IRS-1 tyrosine phosphorylation in the HSP
fraction after okadaic acid treatment was also significantly
decreased and coincided with the large decrease in the IRS-1
protein in this fraction. This decrease in IRS-1 tyrosine phos-
phorylation did not appear to be due to a defect in the IR
tyrosine kinase activity, because insulin-dependent tyrosine
phosphorylation of the IR b-subunit, which is enriched in the
plasma membrane fraction (PM), was unaffected by okadaic
acid (Fig. 5).
The okadaic acid-induced block in IRS tyrosyl phosphoryla-
tion was accompanied by a decrease in the recruitment of the
p85 subunit of PI 3-kinase to the HSP fraction (Fig. 5). While
insulin alone stimulated recruitment of p85 to the HSP, this
effect was almost entirely abolished in the presence of okadaic
acid. It is noteworthy that okadaic acid did not significantly
alter the levels of p85 associated with the HSP fraction in the
basal state. This suggests that the presence of PI 3-kinase in
the adipocyte HSP fraction under basal conditions is probably
not mediated by a direct interaction with IRS-1, and the effects
of okadaic acid on the organization of proteins in this fraction
are somewhat specific.
Effects of PDGF on the Subcellular Distribution of IRS Pro-
teins—Thus far, we have shown that chronic insulin treatment
and okadaic acid independently trigger the release of IRS pro-
teins from the adipocyte HSP fraction into the cytosol (Figs. 2
and 5). Furthermore, both treatments cause a distinct reduc-
tion in the electrophoretic mobility of IRS proteins, both within
the HSP fraction and the cytosol. PDGF has previously been
shown to induce a similar change in the electrophoretic mobil-
ity of IRS-1 (47). In addition, decreases in insulin-stimulated
tyrosyl phosphorylation of IRS-1 and recruitment of PI 3-ki-
nase following PDGF treatment of adipocytes has been re-
ported (48). We examined the effect of a similar PDGF treat-
ment protocol on the subcellular distribution of IRS proteins in
3T3-L1 adipocytes. Extended incubation with PDGF (1 h), led
to a significant dissociation of IRS proteins from the HSP (up to
50%), with a concomitant increase in the cytosolic component
(Fig. 6A). However, the magnitude of this effect was not as
great as that observed using chronic insulin treatment (Fig.
6A). In addition, and unlike the effects of insulin, we did not
observe any detectable electrophoretic shift in IRS-1 or IRS-2
with PDGF in the HSP, although a noticeable decrease was
observed in the cytosolic fraction. Furthermore, PDGF treat-
ment of adipocytes did not significantly impair insulin-stimu-
lated glucose uptake in adipocytes at maximal or submaximal
concentrations of insulin (Fig. 6B). These data suggest that the
moderate loss of IRS proteins from the HSP induced by PDGF
does not significantly alter insulin sensitivity.
DISCUSSION
The strength, duration, and specificity of growth factor sig-
naling may be accomplished, at least in part, by the spatial
compartmentalization of the cognate signal transduction ma-
chinery. In accordance with this notion, we and others have
previously reported that a cohort of insulin-regulatable signal-
ing proteins, including IRS-1, associate with a low density
insoluble fraction in basal adipocytes (29, 31, 33, 40) that we
refer to as the HSP. Biochemical analyses of the HSP indicates
that IRS-1 does not associate with membranes in this fraction
FIG. 4. Effects of wortmannin on the insulin-induced redistri-
bution of IRS proteins in 3T3-L1 adipocytes. Adipocytes were
incubated in the absence or presence of wortmannin (100 nM) for 15 min
and then incubated with insulin (1 mM) plus wortmannin (100 nM) for
1 h. Cells were washed, homogenized, and subjected to differential
centrifugation to obtain high speed pellet (HSP) and cytosol fractions.
A, fractions were resolved by SDS-PAGE and immunoblotted with
antibodies specific for IRS-1 and IRS-2. B, the cytosolic fraction was
resolved by SDS-PAGE and immunoblotted with antibodies specific for
Akt-2. Results representative of six independent experiments are
shown.
FIG. 5. Effects of okadaic acid on the subcellular distribution
of IRS-1, PI 3-kinase, and tyrosine phosphoproteins in 3T3-L1
adipocytes. Adipocytes were incubated with okadaic acid (2.5 mM) for
30 min. Where indicated, insulin was added for the last 15 min of
okadaic acid treatment. Cells were washed and homogenized, and sub-
cellular fractions were prepared. Aliquots (20 mg) of the plasma mem-
brane (PM), high speed pellet (HSP), and cytosol (CYT) fractions were
resolved by SDS-PAGE and immunoblotted with antibodies specific for
IRS-1 (anti-IRS-1), phosphotyrosine (anti-pY), and PI 3-kinase (anti-
p85). Results are representative of two independent experiments.
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(29). In contrast to HSP-associated membrane proteins, such as
GLUT4, IRS-1 remains insoluble in nonionic detergents and
does not exhibit buoyant density in sucrose gradients. The
latter observation is of particular note, because it excludes the
possibility that IRS-1 associates with modified vesicular struc-
tures such as caveolae or clathrin-coated vesicles (49, 50). In
addition to membranes, the HSP contains large protein com-
plexes and cytoskeletal elements (29). Thus, we have proposed
that IRS-1 is associated with the cytoskeleton and that this
protein complex co-fractionates with intracellular membranes.
In this study, we have shown that IRS-2 has similar properties
to IRS-1. A significant proportion of IRS-2 co-fractionates in the
HSP (Fig. 1A), consistent with other studies (34, 43); IRS-2
remains insoluble in nonionic detergents (Fig. 1B), and IRS-2
does not float in dense sucrose solutions (data not shown).
Hence, we conclude that IRS-1 and IRS-2 associate with a large
protein complex in the basal state that has properties charac-
teristic of the cytoskeleton.
What is the function of the HSP pool of IRS proteins? There
are several indications that the HSP represents the location
where insulin signaling is initiated. First, the largest increase
in insulin-stimulated IRS protein-tyrosine phosphorylation oc-
curs in the HSP (Fig. 2, A and B). Second, the increase in
tyrosyl-phosphorylated IRS proteins in the HSP correlates
with the recruitment of PI 3-kinase to this fraction from the
cytosol (Fig. 2A). Third, okadaic acid results in an almost quan-
titative release of IRS-1 from the HSP into the cytosol, and,
despite maintenance of the IR tyrosine kinase activity (20),
there is no detectable insulin-stimulated tyrosine phosphoryl-
ation of IRS proteins in the cytosol (Fig. 5). One initial signal-
ing event is the interaction with the IR, and we suggest that
the cytoskeletal localization of IRS proteins that is present in
the HSP may be required for this to occur efficiently. Consid-
erable evidence suggests that IRS-1 encounters the IR at the
plasma membrane, so we have proposed that this HSP pool of
IRS-1 represents a cytoskeleton that decorates the underside of
the plasma membrane. First, immunofluorescence localization
of tyrosyl-phosphorylated IRS-1 in CHO cells indicates that at
early times (;1 min), after insulin addition there is cell surface
labeling, followed by increased cytosolic staining at later times
(51). Second, inhibition of endocytosis by incubation at 4 °C
(31), potassium depletion (52), or use of a mutant dynamin
allele has little effect on insulin-stimulated tyrosine phospho-
rylation of either IR or IRS-1 (53). Finally, microinjection of a
fusion protein that specifically interacts with the phosphatidy-
linositide product of PI 3-kinase activity, PI 3,4,5-trisphos-
phate, into adipocytes showed pronounced labeling of the
plasma membrane within 1 min of insulin stimulation (54).
Hence, the localization of IRS-1 and IRS-2 to the cytoskeleton
underlying the plasma membrane may allow an efficient inter-
action between the pleckstrin homology and phosphotyrosine
binding domains of these proteins with the intracellular tail of
the IR and thus rapidly promotes tyrosine phosphorylation of
these proteins in response to insulin. Furthermore, the coordi-
nation of these signaling events with the recruitment of PI
3-kinase may ensure the correct localization of this enzyme to
its membrane-bound substrate(s), located at the cell surface.
It has previously been shown that with short term insulin
treatment, IRS-1 translocates from the HSP into the cytosol in
3T3-L1 adipocytes (31). One possibility is that this transloca-
tion event may be necessary to propagate the insulin signal by
allowing the IRS-signaling complex access to the relevant
downstream targets. This does not appear to be the case, at
least for PI 3-kinase, given that downstream targets of this
enzyme are recruited to the cell surface (54). Alternatively, this
translocation event may act as the “off” switch for insulin
action. This implies that the inappropriate release of IRS pro-
teins into the cytosol may disengage IR and IRS proteins,
resulting in desensitization and/or insulin resistance. In sup-
port of this model, we have shown that exposure of adipocytes
to conditions known to cause insulin resistance, namely chronic
insulin or okadaic acid treatment, also stimulate the release of
IRS proteins from the HSP into the cytosol (Figs. 2 and 5,
respectively).
PDGF treatment caused a relatively modest decline in IRS
levels in the HSP (Fig. 6A), whereas the loss with okadaic acid
treatment was almost quantitative (Fig. 5). This is an impor-
tant distinction to make, because preincubation of adipocytes
with PDGF for 60 min prior to insulin treatment does not
impair insulin-stimulated glucose transport (Fig. 6B) (48),
while okadaic acid potently inhibits this process (20, 23, 45, 46).
Similarly, the onset of insulin resistance in cells exposed to
chronic insulin treatment coincides with the loss of more than
90% of IRS protein from the HSP (Fig. 2). These data suggest
that there is a nonlinear relationship between the level of IRS
protein associated with the HSP and the onset of insulin re-
sistance and that a small amount of IRS proteins associated
with the HSP is sufficient to evoke a full biological response to
insulin. We propose that a competent level of IRS proteins is
maintained in the HSP in the presence of short term PDGF
treatment and during several hours of insulin treatment. How-
ever, this threshold cannot be maintained in response to longer
insulin treatment or okadaic acid.
In each of the three experimental regimens used to challenge
the localization of IRS proteins, the function of the insulin
receptor appears to be retained, but the insulin-regulated ty-
rosyl phosphorylation of IRS proteins is decreased (20, 21, 24,
FIG. 6. Effects of PDGF on the subcellular distribution of IRS
proteins and insulin-regulated glucose uptake in 3T3-L1 adipo-
cytes. A, adipocytes were incubated with 1 mM insulin (I) or 50 ng/ml
PDGF (P) or no additions (B) for 1 h. Aliquots of the high speed pellet
(HSP) (30 mg) and cytosol (25 mg) were resolved by SDS-PAGE and
immunoblotted with antibodies specific for IRS-1 or IRS-2. The results
shown are representative of three independent experiments. B, adipo-
cytes were incubated in the absence or presence of 50 ng/ml PDGF for
1 h and subsequently treated with insulin at the noted concentrations
for 15 min. 2-deoxyglucose (2-DOG) uptake was measured in the final 3
min of treatment as outlined under “Experimental Procedures.” The
results depict the mean 6 S.D. of duplicates for each condition and are
representative of two independent experiments.
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48). This observation can be explained based on the model
proposed here, where the translocation of IRS proteins from the
HSP into the cytosol uncouples their phosphorylation from the
insulin receptor simply due to inaccessibility. The possibility
that other mechanisms disrupt IR phosphorylation of IRS pro-
teins in the cytosol, such as an interaction between IRS pro-
teins with cytosolic factors or covalent modification of IRS
proteins, cannot be discounted. The latter mechanism is
thought to be invoked during tumor necrosis factor-a-induced
insulin resistance in adipocytes. Tumor necrosis factor-a leads
to increased serine phosphorylation of IRS-1 and decreased
tyrosine phosphorylation of IRS-1 by the insulin receptor (22).
Enhanced Ser/Thr phosphorylation of IRS proteins has been
proposed to alter the mobility of these molecules during SDS-
PAGE and has been observed in cells exposed to each of the
conditions employed in these studies (23, 24, 47). Interestingly,
we routinely observed the most significant gel shift in the
cytosolic pool of IRS proteins exposed to chronic insulin treat-
ment (Fig. 2A), okadaic acid (Fig. 5), or PDGF (Fig. 6A). Ser/Thr
phosphorylation of IRS proteins has also been proposed to
trigger the translocation of these molecules into the cytosol
(31). However, in wortmannin-treated adipocytes, the electro-
phoretic shift of IRS proteins in response to prolonged insulin
stimulation was blunted, but the translocation to the cytosol
was not impaired (Fig. 4A), suggesting that the two processes
can be uncoupled. This is in agreement with recent studies by
Inoue and colleagues (34), where the release of IRS proteins
from the HSP has been attributed to the phosphorylation of
other proteins contained within this fraction. It is plausible
that serine phosphorylation of IRS proteins occurs simulta-
neously with release from the HSP as a mechanism to prevent
inappropriate interactions with IR. This would ensure accurate
termination of the insulin signal as well as avoiding mislocal-
ization of downstream targeting molecules.
It is conceivable that insulin resistance induced by the shift
of IRS proteins from the HSP may result from one of two
mechanisms in adipocytes. The first mechanism, which may
occur very rapidly and is presumably promoted by okadaic acid,
involves the disengagement of IR from IRS proteins. The sec-
ond mechanism involves down-regulation of the relevant sig-
naling molecules. This mechanism may require a longer dura-
tion to take effect than the first but may be equipotent in terms
of the long term potential to induce insulin resistance. Recent
studies have shown that prolonged insulin stimulation de-
creases the half-life of IRS-1 from 20 to 2.5 h in 3T3-L1 adipo-
cytes (55). In agreement with these findings, we also observed
a net loss of IRS-1 and IRS-2 with chronic insulin treatment
(Figs. 2, A–C). These observations raise the possibility that
release of IRS proteins into the cytosol increases the accessi-
bility to proteases responsible for their down-regulation. This
catabolic state may only be evident under extreme circum-
stances, whereas during normal conditions of transient insulin
elevations, IRS proteins may rapidly recycle between the HSP
and cytosol without significant degradation. The calcium-de-
pendent proteases of the calpain family have been implicated in
the degradation of IRS proteins (56). It is equally possible that
the regulated movement of IRS-1 and IRS-2 corresponds to an
increase in the ubiquitination of these proteins.2 In this regard,
the incremental increases in the molecular weight of cytosolic
IRS-1 and IRS-2 observed in response to chronic insulin (Fig.
2A), okadaic acid (Fig. 5), and PDGF (Fig. 6A) may correspond
to mono- or polyubiquitination of these proteins.
Based on the present studies, we suggest that the intracel-
lular localization of the insulin-specific docking proteins IRS-1
and -2 may play an important role in modulating insulin sig-
naling cascades. Identification of the downstream signaling
molecules that mediate many of insulin’s specific actions, such
as GLUT4 translocation to the cell surface, remain an impor-
tant challenge. However, equally important will be the identi-
fication of the factors in the HSP that anchor IRS proteins
within close proximity of the insulin receptor and subsequently
enhance the efficiency of signaling in response to insulin
stimulation.
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